Antibody-Drug Conjugates and Adverse Events: Improving Identification and Management Among Oncology Nurses Serving Rural and Underserved Communities
Release Date | June 2, 2025 |
Expiration Date | June 2, 2026 |
Format | Webcast |
CE | 1.0 contact hour |
Acknowledgement
This activity is provided by Talem Health and RME Collaborative.
This online program is recorded content from the live session at Oncology Nursing Conference in March 2025 and is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Credit Available
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Target Audience
This activity is designed specifically for nurse practitioners, nurses, and other nursing professionals who provide cancer care to patients from rural and underserved communities.
Program Overview
The use of antibody-drug conjugates (ADCs) has greatly expanded in recent years due to promising outcomes in various cancer types. Despite their efficacy, ADCs are frequently associated with adverse events that require dose reductions, therapy interruptions, or discontinuation. As a result, oncology nurses play a central role in identifying, monitoring, and managing patients, particularly in rural and underserved communities that face oncologist shortages and limited access to multidisciplinary care. In this on-demand CE activity, expert faculty will review available ADC therapies, mechanisms that can cause clinical toxicity, and guidance for recognizing and managing common treatment-related adverse events. Strategies to enhance communication and improve education among patients on ADC therapy in rural and underserved communities will also be discussed.
This enduring activity is a recorded session from Oncology Nursing Conference that took place on March 8, 2025.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate common adverse events of ADC therapy and the mechanisms contributing to clinical toxicity
- Apply evidence-based strategies and best practices to identify, monitor, and mitigate adverse events associated with ADC therapy
- Integrate strategies to improve communication with patients, care coordination, and education for patients being treated with ADCs
Faculty

Marianne J. Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature Oncology Service Line
Oncology Nurse Practitioner
Yale New Haven Hospital and Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, CT
Lance F. Ortega, MBA, BSN, RN, OCN
Executive Director, Clinical Operations
Texas Oncology
Dallas-Fort Worth, TX
Joint Accreditation Statement
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Marianne J. Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships to disclose.
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CE credit, participants must:
- Read the CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Supported Browsers:
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
Media
Internet activity
Fee Information
There is no fee for this educational activity.
Contact Information
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.